date name shares transaction value  david l mahoney director    disposition at  per share   david l mahoney director    derivativenonderivative trans at  per share   david l mahoney director    disposition at  per share   david l mahoney director    derivativenonderivative trans at  per share   david l mahoney director    disposition at  per share   david l mahoney director    derivativenonderivative trans at  per share   david l mahoney director    disposition at  per share   david l mahoney director    derivativenonderivative trans at  per share   gary charles robb chief financial officer    acquisition at  per share   longitude capital management co llc director    disposition at  per share   longitude capital management co llc director    disposition at  per share   longitude capital management co llc director    disposition at  per share   longitude capital management co llc director    disposition at  per share   longitude capital management co llc director    disposition at  per share   longitude capital management co llc director    disposition at  per share   longitude capital management co llc director    disposition at  per share   longitude capital management co llc director    disposition at  per share   daniel mark bradbury director    gift at  per share  newslatestcompanyuscort marketwatch news on cort corcept therapeutics started at buy with  stock price target at ladenburg thalmann  am feb    tomi kilgore  russell  stocks youre glad you never heard of  pm may    blogsmarketwatchcom updates advisories and surprises  pm may    marketwatch aegerion perrigo corcept all tumble on rough earnings difficult news  am may    russ britt corcept shares slide  after it halts drug trial  am may    ciara linnane insider filings one way to track tricky microcap biotechs  pm oct    blogsmarketwatchcom corcept therapeutics plans to sell m shares  am july    marketwatchcom tuesday’s biggest gaining  declining stocks  pm feb    kate gibson us markets sustain fedinduced breakout  am sept    michael ashbaugh sp dow edge within view of record territory  am sept    michael ashbaugh tuesdays biggest stock gainers and decliners  pm sept    marketwatch corcept shares soar as fda opens corlux application  pm sept    gabriel madway fridays biggest stock gainers and decliners  pm june    marketwatch correct thursdays biggest stock gainers and decliners  pm april    michael baron corcept to switch to nasdaq capital market shares rise  am april    gabriel madway drug stocks mixed lilly dips on fda request  pm sept    val brickates kennedy fridays biggest stock gainers and decliners  pm sept    michael baron corcept therapeutics down  at  cents  am sept    tomi kilgore corcept depression treatment study results negative  am sept    michael baron corcept therapeutics says phase iii corlux trial negative  am sept    thomas middleton loading more headlines newsnonmarketwatchcompanyuscort other news on cort could this small biotech break out on a tieup with eli lilly  am today am july    investors business daily vertex vrtx triple combination cf studies data positive  am july    zackscom is it too late to get in on this millionairemaker stock  am july    motley fool corcept therapeutics focuses on korlyms label expansion  pm july    zackscom why is corcepts stock up more than  so far this year  am july    zackscom corcept therapeutics incorporated in  charts  am june    motley fool plains gp holdings lp pagp and green plains inc gpre lead today’s top  investor filings  am june    investorplacecom can this biotech stock with  eps growth launch new breakout  am june    investors business daily pharma stock with tripledigit growth forming blotchy base  am may    investors business daily alexion at nearly year low after announcing exits of  execs  pm may    investors business daily  of the cheapest biotech stocks in the world  am may    motley fool sitrin capital management llc buys pfizer inc target corp sells walmart stores inc chevron   am may    gurufocuscom q corcept therapeutics inc  pm may    edgar online  edg  q k is there more upside edition   pm may    seeking alpha corcept therapeutics cort ceo joseph belanoff on q  results  earnings call transcript  pm may    seeking alpha notable earnings after monday’s close  pm april    seeking alpha bristolmyers bmy beats on q earnings ups  view  am april    zackscom heres why corecept therapeutics incorporated had a rough day  pm april    motley fool nivalis nvls shares down after merger deal with alpine  am april    zackscom this biotech leader breaks out defying sector odds  am april    investors business daily loading more headlines at a glance corcept therapeutics inc  commonwealth drive menlo park california  phone   industry pharmaceuticals sector health carelife sciences fiscal yearend  view sec filings revenue m net income m  sales growth  employees  annual report for cort newspressreleasecompanyuscort press releases on cort research reports initiation on biotech stocks  corcept therapeutics curis ovascience and vanda pharma  am may    pr newswire  prf blog coverage synthetic biologics wins breakthrough therapy designation for its clostridium difficile infection candidate  am may    accesswire corcept therapeutics announces presentations on mifepristone for the treatment of patients with hypercortisolism at the american association of clinical endocrinologists th annual congress  am may    marketwired corcept therapeutics announces first quarter  financial results raises  revenue guidance and provides corporate update  pm may    marketwired investor network corcept therapeutics incorporated to host earnings call  am may    accesswire corcept therapeutics to announce first quarter financial results and corporate update and host conference call  pm april    marketwired corcept therapeutics announces fourth quarter and fullyear  financial results increases  revenue guidance  am march    marketwired corcept therapeutics announces preliminary fourth quarter and fullyear  financial results and corporate update provides  revenue guidance  pm jan    marketwired research reports coverage on biotech stocks  pharmathene corcept therapeutics navidea biopharma and inotek pharma  am jan    pr newswire  prf corcept therapeutics to announce preliminary  financial results provide  revenue guidance and corporate update and host conference call  pm jan    marketwired research reports coverage on biotech stocks  idera pharma bluebird bio corcept therapeutics and phaserx  am dec    pr newswire  prf corcept therapeutics announces encouraging results of phase  trial of mifepristone plus eribulin in triplenegative breast cancer  pm dec    marketwired corcept therapeutics announces third quarter  financial results and provides corporate update  pm nov    marketwired corcept therapeutics to announce third quarter  financial results and corporate update and host conference call  am oct    marketwired corcept therapeutics announces second quarter  financial results and provides corporate update  pm aug    marketwired corcept therapeutics to announce second quarter  financial results and corporate update and host conference call  pm july    marketwired trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york open marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pboeing earnings management will likely make a big deal about its services business pno retreat fed to stick to plans for rate hike balancesheet selloff this year pconstellation brands boston beer shares slide after goldman sachs downgrades pamd puts intel in the crosshairs with fastandcheap threadripper chip pwhy you should be worried about this part of the new york realestate market pbarrons bounce meaty gains for leucadia pgold settles lower ending session streak of gains phow housekeepers takeout food and grocery delivery are making us happier pdow sp  edge lower while nasdaq sets intraday record pboston beer downgraded to sell at goldman sachs pcprrected constellation brands downgraded to neutral at goldman sachs pcorrected goldman sachs sets constellation brands price target at  p‘game of thrones’ science let’s take a closer look at that greyscale poil prices finish higher after news of saudi pledge to cut exports nigeria plans to cap output pconstellation brands shares down  pmove over airbnb here’s how to rent out your home for a lot more money p‘robot parents’ can even read your child bedtime stories pcompanies do better when ceo pay dwarfs average worker study finds ptrump administration stymies push for improved climaterisk disclosure among companies pnever ever say these things to a coworker loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  corcept therapeutics  wikipedia corcept therapeutics from wikipedia the free encyclopedia jump to navigation search corcept therapeutics inc is a pharmaceutical company developing products that regulate the effects of cortisol the stress hormone and deal with severe metabolic disorders the company is a publicly traded company on nasdaq under the symbol cort corcept therapeutics inc type public traded as nasdaq cort industry pharmaceutical industry founded  headquarters united states products pharmaceutics website wwwcorceptcom contents  treatments  type ii diabetes  psychotic depression  other metabolic disorders  patent rights  references  external links treatmentsedit corcept therapeutics inc has developed treatments mainly focusing on solving metabolic disorders and related problems and have several experimental and onsale drugs released type ii diabetesedit one of the principle drugs that the company has been developing is korlym which is an oral daily medication for patients with type ii diabetes mellitus or glutose intolerance and those who failed or might not tolerate surgery in  after being offered since  in the us the drug was further commercialized to the market outside the states and reached the global medical field since the companys partnership with idis access program was approved and launched this is the first therapy approved by us food and drug administration fda for patients with endogenous cushings syndrome psychotic depressionedit from  the company has been studying the psychotic features of depression and developing oral medication for the symptoms in recent years two of the main trials were conducted with the drug corlux which is a oncedaily treatment given to patients mainly in the united states other metabolic disordersedit the company has also been studying treatment for other metabolic disorders in april  results of two preclinical studies were announced by the company demonstrating an effect that can prevent weight gain associated with treatment with olanzapine in december  the company announced plans to extend its development program for glucocorticoid receptor gr antagonists including mifepristone into oncology patent rightsedit in december  corcept therapeutics inc licensed patent rights with the university of chicagos center for technology development  ventures and started investigating new drug application with the us food and drug administration fda on metastatic triplenegative breast cancer tnbc referencesedit  httpwwwcorceptcom  httpsfinanceyahoocomqprscortprofile  httpswwwgooglecomfinancecid  httpswwwreuterscomfinancestockscortokeydevelopmentsarticle  httpwwwcorceptcomproducts  httpswwwreuterscomfinancestockscompanyprofilerpcsymbolcorto  httpswwwreuterscomfinancestockscompanyprofilerpcsymbolcorto  corcept therapeutics announces oncology development program   httpwwwprnewswirecomnewsreleasescortmedannouncesacquisitionofzipsordiclofenacpotassiumfromxanodynepharmaceuticalsinchtml external linksedit company website retrieved from httpsenwikipediaorgwindexphptitlecorcepttherapeuticsoldid categories pharmaceutical companies of the united statescompanies listed on nasdaqhealth care companies based in californiahidden categories pages using infobox company with unsupported parameters navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view corcept therapeutics  wikipedia corcept therapeutics from wikipedia the free encyclopedia jump to navigation search corcept therapeutics inc is a pharmaceutical company developing products that regulate the effects of cortisol the stress hormone and deal with severe metabolic disorders the company is a publicly traded company on nasdaq under the symbol cort corcept therapeutics inc type public traded as nasdaq cort industry pharmaceutical industry founded  headquarters united states products pharmaceutics website wwwcorceptcom contents  treatments  type ii diabetes  psychotic depression  other metabolic disorders  patent rights  references  external links treatmentsedit corcept therapeutics inc has developed treatments mainly focusing on solving metabolic disorders and related problems and have several experimental and onsale drugs released type ii diabetesedit one of the principle drugs that the company has been developing is korlym which is an oral daily medication for patients with type ii diabetes mellitus or glutose intolerance and those who failed or might not tolerate surgery in  after being offered since  in the us the drug was further commercialized to the market outside the states and reached the global medical field since the companys partnership with idis access program was approved and launched this is the first therapy approved by us food and drug administration fda for patients with endogenous cushings syndrome psychotic depressionedit from  the company has been studying the psychotic features of depression and developing oral medication for the symptoms in recent years two of the main trials were conducted with the drug corlux which is a oncedaily treatment given to patients mainly in the united states other metabolic disordersedit the company has also been studying treatment for other metabolic disorders in april  results of two preclinical studies were announced by the company demonstrating an effect that can prevent weight gain associated with treatment with olanzapine in december  the company announced plans to extend its development program for glucocorticoid receptor gr antagonists including mifepristone into oncology patent rightsedit in december  corcept therapeutics inc licensed patent rights with the university of chicagos center for technology development  ventures and started investigating new drug application with the us food and drug administration fda on metastatic triplenegative breast cancer tnbc referencesedit  httpwwwcorceptcom  httpsfinanceyahoocomqprscortprofile  httpswwwgooglecomfinancecid  httpswwwreuterscomfinancestockscortokeydevelopmentsarticle  httpwwwcorceptcomproducts  httpswwwreuterscomfinancestockscompanyprofilerpcsymbolcorto  httpswwwreuterscomfinancestockscompanyprofilerpcsymbolcorto  corcept therapeutics announces oncology development program   httpwwwprnewswirecomnewsreleasescortmedannouncesacquisitionofzipsordiclofenacpotassiumfromxanodynepharmaceuticalsinchtml external linksedit company website retrieved from httpsenwikipediaorgwindexphptitlecorcepttherapeuticsoldid categories pharmaceutical companies of the united statescompanies listed on nasdaqhealth care companies based in californiahidden categories pages using infobox company with unsupported parameters navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view corcept therapeutics  wikipedia corcept therapeutics from wikipedia the free encyclopedia jump to navigation search corcept therapeutics inc is a pharmaceutical company developing products that regulate the effects of cortisol the stress hormone and deal with severe metabolic disorders the company is a publicly traded company on nasdaq under the symbol cort corcept therapeutics inc type public traded as nasdaq cort industry pharmaceutical industry founded  headquarters united states products pharmaceutics website wwwcorceptcom contents  treatments  type ii diabetes  psychotic depression  other metabolic disorders  patent rights  references  external links treatmentsedit corcept therapeutics inc has developed treatments mainly focusing on solving metabolic disorders and related problems and have several experimental and onsale drugs released type ii diabetesedit one of the principle drugs that the company has been developing is korlym which is an oral daily medication for patients with type ii diabetes mellitus or glutose intolerance and those who failed or might not tolerate surgery in  after being offered since  in the us the drug was further commercialized to the market outside the states and reached the global medical field since the companys partnership with idis access program was approved and launched this is the first therapy approved by us food and drug administration fda for patients with endogenous cushings syndrome psychotic depressionedit from  the company has been studying the psychotic features of depression and developing oral medication for the symptoms in recent years two of the main trials were conducted with the drug corlux which is a oncedaily treatment given to patients mainly in the united states other metabolic disordersedit the company has also been studying treatment for other metabolic disorders in april  results of two preclinical studies were announced by the company demonstrating an effect that can prevent weight gain associated with treatment with olanzapine in december  the company announced plans to extend its development program for glucocorticoid receptor gr antagonists including mifepristone into oncology patent rightsedit in december  corcept therapeutics inc licensed patent rights with the university of chicagos center for technology development  ventures and started investigating new drug application with the us food and drug administration fda on metastatic triplenegative breast cancer tnbc referencesedit  httpwwwcorceptcom  httpsfinanceyahoocomqprscortprofile  httpswwwgooglecomfinancecid  httpswwwreuterscomfinancestockscortokeydevelopmentsarticle  httpwwwcorceptcomproducts  httpswwwreuterscomfinancestockscompanyprofilerpcsymbolcorto  httpswwwreuterscomfinancestockscompanyprofilerpcsymbolcorto  corcept therapeutics announces oncology development program   httpwwwprnewswirecomnewsreleasescortmedannouncesacquisitionofzipsordiclofenacpotassiumfromxanodynepharmaceuticalsinchtml external linksedit company website retrieved from httpsenwikipediaorgwindexphptitlecorcepttherapeuticsoldid categories pharmaceutical companies of the united statescompanies listed on nasdaqhealth care companies based in californiahidden categories pages using infobox company with unsupported parameters navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view cortnasdaq cm stock quote  corcept therapeutics inc  bloomberg markets error could not add to watchlist x  watchlist corcept therapeutics inc cortus nasdaq cm usd   as of  pm edt  open  day range    volume  previous close  wk range     yr return  before its here its on the bloomberg terminal learn more open  day range    volume  previous close  wk range     yr return  ytd return  current pe ratio ttm  earnings per share usd ttm  market cap b usd  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases there are currently no news stories for this ticker please check back later  amyotrophic lateral sclerosis therapeutic pipeline market  key players orphazyme aps apopharma inc and biohealthonomics  corcept therapeutics announces presentations on mifepristone for the treatment of patients with hypercortisolism at the  corcept therapeutics announces first quarter  financial results raises  revenue guidance and provides corporate update  corcept therapeutics to announce first quarter financial results and corporate update and host conference call  corcept therapeutics announces fourth quarter and fullyear  financial results increases  revenue guidance  corcept therapeutics announces preliminary fourth quarter and fullyear  financial results and corporate update provides  there are currently no press releases for this ticker please check back later profile corcept therapeutics inc is a pharmaceutical company that discovers and develops drugs for the treatment of severe metabolic and psychiatric disorders the companys lead product modulates the effect of cortisol also known as the stress hormone by selectively blocking the binding of cortisol to one of its two known receptors the grii receptor address  commonwealth drivemenlo park ca united states phone  website wwwcorceptcom executives board members joseph k belanoff presidentceocofounder gary charles robb charlie chief financial ofcrsecyir robert s fishman chief medical officer show more cort stock price  news  corcept therapeutics inc  wall street journal dow jones a news corp company news corp is a network of leading companies in the worlds of diversified media news education and information services dow jones barrons bigcharts djx dow jones newswires factiva financial news mansion global marketwatch newsmart newsplus private markets risk  compliance wsjcom wsj pro wsj conference wsj video news corp big decisions business spectator checkout harper collins new york post proptiger rea realtorcom storyful the australian the sun the times djia ▲     sp  ▲     nasdaq ▲     us  yr ▲  yield    crude oil ▲     euro ▲     subscribe now sign in the wall street journal us edition us asia europe india  china  japan july   todays paper sections my journal home world us politics economy business tech markets opinion arts life real estate todays paper show all sections hide all sections world home africa asia canada china europe latin america middle east economy world video us home economy law new york politics real time economics washington wire journal report us video whats news podcast politics home washington wire politics video wsjnbc news poll economy home real time economics economic forecasting survey economy video business home management techwsjd aerospace  defense autos  transportation commercial real estate consumer products energy entrepreneurship financial services food  services health care hospitality law manufacturing media  marketing natural resources retail cfo journal cio journal cmo today logistics report risk  compliance heard on the street business video journal report business podcast tech home cio journal geoffrey fowler christopher mims joanna stern li yuan billion dollar startup club tech video tech podcast startup stock trader markets home bonds commercial real estate commodities  futures currencies deals financial services funds stocks your money heard on the street moneybeat wealth adviser ahead of the tape cfo journal journal report market data markets video markets podcast moneybeat podcast watching your wealth podcast opinion home james freeman william a galston daniel henninger holman w jenkins william mcgurn peggy noonan mary anastasia ogrady jason riley kimberley a strassel books film television theater art masterpiece series music dance opera exhibition cultural commentary editorials commentary letters to the editor the weekend interview potomac watch podcast foreign edition podcast opinion video notable  quotable best of the web newsletter morning editorial report newsletter arts home books film television theater art masterpiece series arts video wsj magazine life home careers cars food  drink health ideas real estate science sports style  fashion travel life video wsj magazine wsj puzzles the future of everything real estate home commercial real estate house of the day mansion real estate video hide all sections aim higher reach further get the wall street journal  for  weeks subscribe now sign in reveal navigation options subscribe sign in corcept therapeutics inc cort us nasdaq search view all companies real time  pm edt   usd   volume  volume   day avg vol   day range     week range        d  d  m  m ytd  y  y   advanced charting compare compare to benchmark djia sp  global dow nasdaq health carelife sciences compare to add open  prior close    day cort  djia  sp mid cap   health carelife sciences  overview overview profile financials income statement balance sheet cash flow research  ratings historical prices options advanced charting news corcept therapeutics inccort significant news only  press release research reports initiation on biotech stocks  corcept therapeutics curis ovascience and vanda pharma press release  press release corcept therapeutics announces presentations on mifepristone for the treatment of patients with hypercortisolism at the american association of clinical endocrinologists th annual congress press release  dow jones newswires corcept therapeutics files k  regulation fd dow jones newswires  press release corcept therapeutics announces first quarter  financial results raises  revenue guidance and provides corporate update press release  press release  cort  investor network corcept therapeutics incorporated to host earnings call press release load more key stock data  pe ratio ttm the price to earnings pe ratio a key valuation measure is calculated by dividing the stocks most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing  month period earnings per share ttm a companys net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding market capitalization reflects the total market value of a company market cap is calculated by multiplying the number of shares outstanding by the stocks price for companies with multiple common share classes market capitalization includes both classes shares outstanding number of shares that are currently held by investors including restricted shares owned by the companys officers and insiders as well as those held by the public public float the number of shares in the hands of public investors and available to trade to calculate start with total shares outstanding and subtract the number of restricted shares restricted stock typically is that issued to company insiders with limits on when it may be traded dividend yield a companys dividend expressed as a percentage of its current stock price key stock data pe ratio ttm   eps ttm  market cap  b shares outstanding  m public float  m yield cort has not issued dividends in more than  year latest dividend na exdividend date na  shares sold short the total number of shares of a security that have been sold short and not yet repurchased change from last percentage change in short interest from the previous report to the most recent report exchanges report short interest twice a month percent of float total short positions relative to the number of shares available to trade short interest  shares sold short  m change from last  percent of float   money flow uptickdowntick ratio money flow measures the relative buying and selling pressure on a stock based on the value of trades made on an uptick in price and the value of trades made on a downtick in price the updown ratio is calculated by dividing the value of uptick trades by the value of downtick trades net money flow is the value of uptick trades minus the value of downtick trades our calculations are based on comprehensive delayed quotes stock money flow uptickdowntick trade ratio    net money flow   money flow gives a snapshot of relative buying and selling pressure in a stock a ratio above one suggests greater buying pressure below one suggests greater selling advertisement competitors cort company change pe ttm bmrn biomarin pharmaceutical inc    ipxl impax laboratories inc    nvs novartis ag adr    bmy bristolmyers squibb co    jnj johnson  johnson    lly eli lilly  co    pfe pfizer inc    myl mylan nv    cbio catalyst biosciences inc    mnkd mannkind corp    more information on cort competitor data provided by capital cube profile cort corcept therapeutics inc engages in the development of drugs for the treatment of severe psychiatric neurological and metabolic disorders it focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol its products  commonwealth drive menlo park california  united states email website map employees  sector pharmaceuticals sales or revenue  m industry health carelife sciences y sales change  fiscal year ends december  download reports james n wilson chairman joseph k belanoff president chief executive officer director  md gary charles robb secretary  chief financial officer hazel hunt senior vice presidentresearch more research  ratings corcept therapeutics inccort pershare earnings actuals and estimates quarterly annual cort will report fy  earnings on  cort will report q earnings on  actual analyst range consensus     actual   actual   actual   actual     q q q q q q     actual      fy  fy  fy  fy  q  estimate trends current   month ago   months ago  q  estimate trends current   month ago   months ago  fy  estimate trends current   month ago   months ago  fy  estimate trends current   month ago   months ago  more financials corcept therapeutics inccort quarterly annual net income  m m m  m mar  jun  sep  dec  mar   m  m m m      mar  quarter trend net income growth  sales or revenue  m sales or revenue growth  ebitda  m  year trend net income growth  sales or revenue  m sales or revenue growth  ebitda  m more overview notes  data providers realtime us stock quotes reflect trades reported through nasdaq only international stock quotes are delayed as per exchange requirements indexes may be realtime or delayed refer to time stamps on index quote pages for information on delay times quote data except us stocks provided by six financial information data is provided as is for informational purposes only and is not intended for trading purposes six financial information a does not make any express or implied warranties of any kind regarding the data including without limitation any warranty of merchantability or fitness for a particular purpose or use and b shall not be liable for any errors incompleteness interruption or delay action taken in reliance on any data or for any damages resulting therefrom data may be intentionally delayed pursuant to supplier requirements all of the mutual fund and etf information contained in this display was supplied by lipper a thomson reuters company subject to the following copyright  thomson reuters all rights reserved any copying republication or redistribution of lipper content including by caching framing or similar means is expressly prohibited without the prior written consent of lipper lipper shall not be liable for any errors or delays in the content or for any actions taken in reliance thereon bond quotes are updated in realtime source tullett prebon currency quotes are updated in realtime source tullet prebon fundamental company data and analyst estimates provided by factset copyright factset research systems inc all rights reserved advertisement corcept therapeutics home nbsp nbsp tweet menu  about corceptaace cap awardkorlym awarddiscovery  developmentexecutive teamboard of directorscontact uspatientspatient advocate programpatient resourcesphysiciansfield supportprofessional eventsmedical informationeducational grantsoutside the usproductskorlym®korlym supportresearchdiscovery researchclinical trialspublicationsinvestigator initiated studiescompassionate use expanded access careers associate director of formulation clinical sales specialist clinical trial assistant clinical trial manager director medical affairs manager managed care  customer operations senior clinical research associate scra senior manager quality management systems vice president endocrinology md vice president managed care  customer operations mcco investorsnewseventsfinancial informationanalyst coveragecorporate governance go contact us committed to innovative treatments for patients with severe metabolic and oncologic disorders learn more leading the fieldin the discovery of drugs that modulatethe effects of cortisol learn more         recent news may   corcept therapeutics announces presentations on mifepristone for the treatment of patients with hypercortisolism at the american association of clinical endocrinologists th annual congress may   corcept therapeutics announces first quarter  financial results raises  revenue guidance and provides corporate update april   corcept therapeutics to announce first quarter financial results and corporate update and host conference call read all news corcept therapeutics is a leader in the discovery and development of drugs that regulate the effects of cortisol corcept’s scientific expertise surrounding the regulation of cortisol has led to the discovery of an extensive library of novel compounds that may ultimately address lifethreatening diseases for patients learn more for physicians learn more about corceptaace cap awardkorlym awarddiscovery  developmentexecutive teamboard of directorscontact uspatientspatient advocate programpatient resourcesphysiciansfield supportprofessional eventsmedical informationeducational grantsoutside the usproductskorlym®korlym supportresearchdiscovery researchclinical trialspublicationsinvestigator initiated studiesinvestigator initiated studiescompassionate use expanded accesscareers associate director of formulation clinical sales specialist clinical trial assistant clinical trial manager director medical affairs manager managed care  customer operations senior clinical research associate scra senior manager quality management systems vice president endocrinology md vice president managed care  customer operations mcco investorsnewseventsfinancial informationanalyst coveragecorporate governance  corcept therapeutics terms of use  privacy policy builtzoomedia you are now leaving this website if you would like to continue click continue cancel continue bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one